Podcasts about bcps

Listen in as our expert panel discusses medications for management of opioid use disorder. They'll review strategies to optimize buprenorphine use and clarify the role of methadone and naltrexone.Special guest:Tyler J. Varisco, PharmD, PhDUniversity of Houston College of Pharmacy Assistant Professor, Department of Pharmaceutical Health Outcomes and PolicyAssistant Director, The PREMIER CenterYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLM, Clinical Associate Professor of Family Medicine for the Prisma Health/USC School of Medicine Greenville Family Medicine Residency Program at the University of South Carolina School of Medicine, GreenvilleCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor of Pharmacy Practice at the Oregon Health and Science UniversityFor the purposes of disclosure, Dr. Varisco reports a financial relationship [cardiology, inflammatory bowel disease] with HEALIX Infusion Therapy (research consultant).The other speakers have nothing to disclose.  All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in March 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: FAQ: Management of Opioid Use DisorderChart: Treatment of Opioid WithdrawalFAQ: Treatment of Acute Pain in Opioid Use DisorderFAQ: Meds for Opioid OverdoseSend us a textIf you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Event Objectives:Describe the different types of gene therapy.Describe the different vectors used.Describe some of the FDA approved products in pediatrics.Claim CME Credit Here!

Join endocrine experts Lubaina S. Presswala, DO, FACOI, FACE; Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES, FADCES; and Viral N. Shah, MD, FACE, as they explore the latest in continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems for managing diabetes. In this episode, they discuss the practical applications of diabetes technology, patient selection, shared decision-making, and considerations for device use in specific populations, including athletes and pregnant individuals. This conversation provides valuable insights to help clinicians navigate device options and enhance outcomes across diverse patient scenarios.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jason Ackrivo, MD, MSCE Guest: Bethany Lussier, MD Respiratory decline in patients with neuromuscular diseases and mitochondrial myopathies can be challenging to identify, especially because its early signs may be subtle and vary from person to person. However, knowing how to evaluate a patient's respiratory function is key to improving outcomes and quality of life. Joining Dr. Charles Turck to discuss this importance and provide recommendations for optimizing respiratory care are Drs. Jason Ackrivo and Bethany Lussier. Dr. Ackrivo is an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania, and Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Pulmonary and Critical Care Medicine.

In a wide-ranging interview, Battle Creek Public Schools Superintendent Dr. Kim Carter returns to Community Matters. This time, Carter offers insight into how possible department of education restructuring at the national level could affect Battle Creek.The superintendent also updates listeners on a bond request which will not result in a tax increase, as well as a new school building set to open - and a series of listening sessions she plans with the community.Episode ResourcesMore Info: 2025 BCPS BondNorthwestern Academy of Visual and Performing ArtsABOUT COMMUNITY MATTERSFormer WBCK Morning Show host Richard Piet (2014-2017) returns to host Community Matters, an interview program focused on community leaders and newsmakers in and around Battle Creek. Community Matters is heard Saturdays, 8:00 AM Eastern on WBCK-FM (95.3) and anytime at battlecreekpodcast.com.Community Matters is sponsored by Lakeview Ford Lincoln and produced by Livemic Communications.

Craig Williams, PharmD, BCPS, FNLA, Clinical Professor, OSU/OHSU PharmD Program, Division of Family Medicine, Oregon Health Sciences UniversityCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link: ⁠⁠https://forms.office.com/r/cZNV37pxK2⁠ (or copy & paste into your browser)Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee & Faculty Disclosure: The planning committee and faculty have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. All financial relationships (if any) have been mitigated.Original Date: April 15, 2025End Date: April 15, 2026

Craig Williams, PharmD, BCPS, FNLA, Clinical Professor, OSU/OHSU PharmD Program, Division of Family Medicine, Oregon Health Sciences UniversityCME Credit Available for all Providence ProvidersIn order to claim CME credit, please click on the following link: ⁠⁠https://forms.office.com/r/cZNV37pxK2⁠ (or copy & paste into your browser)Accreditation Statement: Providence Oregon Region designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1  creditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Providence Oregon Region is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Planning Committee & Faculty Disclosure: The planning committee and faculty have indicated no relevant financial relationships with an ACCME-defined ineligible company. Their planning contributions were evidence-based and unbiased. All financial relationships (if any) have been mitigated.Original Date: April 15, 2025End Date: April 15, 2026

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog There is a new federal rule for lab companies that requires them to report your blood tests to you as soon as they are finished, often even before your doctor has seen them.  This rule, deemed unreasonable, was established by individuals without medical expertise (politicians), who know little about interpreting lab data or the workings of doctor's offices. Sending your lab results to you before doctors can assess them is not a decision rooted in sound medical practice but rather in the notion of individual freedom. While this is important, it does not compare to having an expert interpret your results with you. The law requiring that your lab results be sent to you as soon as they are completed does not consider the fact that these results are not designed for laymen to interpret. Additionally, lab results are meant to be analyzed alongside a patient's medical history, age, gender, and medications.  The results are not tailored to report information specific to your situation, which is how a doctor would interpret them. Lab results often lack layperson-friendly explanations. This new protocol can cause anxiety, as patients may panic over results that appear abnormal, even if they are normal for their specific medical condition and treatment. Furthermore, lab companies only request your age and gender. The factors that doctors evaluate when interpreting your results are diverse and numerous, each influencing the overall interpretation. What are the considerations that doctors add to their interpretation? Menopausal status Medical conditions Healthy normal for young and healthy adults The newest recommended ranges for health Body weight Other lab values seen on the same report The problem with you getting your own lab and interpreting it as written is multifactorial: The lab is sent to you digitally with very little explanation except for reference ranges. There is no information about who you are being compared to. Other women, both men and women? Old women? Young women? Women with symptoms or women who are well without symptoms.  The reporting of the lab results to a patient directly may hide problems that need action or create fears that are unnecessary. Anxiety over your results will continue until your doctor's appointment to discuss … so you may experience unnecessary worry in many circumstances. Reference ranges make many assumptions, but labs don't input vital information about you into their computer. your age of menopause, your weight your height (or BMI) previous illnesses and your medications. if you are on hormones or testosterone   Here is a good example. The test for pituitary hormones FSH and LH. When a woman aged 45 is menopausal, and has a very high FSH and LH, the lab says it is “normal” (in the reference range), yet the woman is having severe hot flashes, night sweats, anxiety, and insomnia.  That is not healthy or “normal”. The same two tests can be used to determine if a person is menopausal. Let's say a 42-year-old woman has elevated FSH and LH, but her estradiol is very high (200-300). To the layperson, this looks like menopause, but in reality, it is the picture of ovulation, not menopause. One has to look at another test, estradiol, to determine whether she is premenopausal and ovulating or menopausal (her estradiol would be very low, and FSH and LH would be high). See the problem? Reference Ranges don't tell you what the doctor is looking for. The same two tests, FSH and LH, are used to diagnose polycystic ovaries (PCO) too.  In women without PCO, the FSH is higher than the LH, but if the LH is greater than the FSH, the diagnosis of PCO should be considered! There is no information about this interpretation in the lab report. Falling within the reference range doesn't guarantee health or absence of symptoms. If patients are to interpret their own lab results, reference ranges should reflect health in every possible scenario. FSH and LH are influenced by BCPs and menopausal HRT. Lab results should be interpreted considering the information regarding BCPs or ERT that the patient is taking. When women are on BCPs and HRT or ERT, their FSH and LH levels are suppressed to an extremely low point. If you are unaware that the patient is taking these hormones, it may appear that the diagnosis is pituitary failure affecting estrogen levels and ovulation. Only doctors can interpret this test. There should truly be a “normal” range for those undergoing hormone replacement therapy, along with a reference range that reflects overall health, rather than merely the average for your geographical area in the US or your age group. Please make an appointment with your doctor to review your lab results so you can understand how they are interpreted. If you have questions about your lab results that are concerning you, schedule a time to discuss them with your doctor. Doctors don't have the time to explain results over the phone or through email—that is what appointments are meant for. Phone calls to doctors' offices are not intended for lab result interpretation. You or your insurance will not compensate the doctor or NP for this service over the phone.   The reference ranges for many tests and medical situations are actually wrong. If you aren't trained as a doctor or Nurse practitioner who interprets metabolic lab results every day, you could get the wrong diagnosis!!! For example, when evaluating a patient for insulin resistance, the reference range was officially changed almost two decades ago. Still, the lab companies have left the normal range very high (insulin> 18). In the revised range, fasting insulin diagnoses insulin resistance if the value is > 10. The resulting outcome is that many people are not diagnosed at a time when they can be easily treated without drugs and are told that they are “normal” when they are really experiencing insulin resistance. This is misleading and just wrong! Lab values are not adjusted to your individual situation.   Many tests are adjusted for gender; however, some are specifically adjusted for women who are menstruating regarding H/H. In other words, men and women have different “normal” H/H levels in the reference range. Women who do not menstruate or who are menopausal should be compared to the same reference range as men, but that does not happen. This leads to menopausal women, who are normal, often being told they have too many red blood cells when that is not the case. Conversely, menopausal women who are truly anemic are told they are normal, which means it takes longer to diagnose their anemia from colon cancer! The H/H should have a reference range that is considered “normal” for a woman's stage in life, depending on whether she is experiencing menstrual periods or not. Many reference ranges are averages for regions of the US and vary between lab companies; therefore, they are not reliable values for comparing patients.   For instance, the Homocysteine test has a normal range that is relatively high, and each lab has different reference ranges. This test serves as a screening tool for MTHFR genetic risk related to embolic stroke and heart disease.   The suggested treatment involves methylated B vitamins; however, the interpretation on the lab printout advises taking B12 and folic acid, which, in my experience, tends to increase the number rather than decrease it. Reference ranges for nutrients, vitamins, and minerals reflect the minimum levels needed for survival, not optimal health. For example, B12 reference range levels for B12 blood levels are listed as 200-1100 pg/ml, yet I was trained to try to achieve 400 -1500 pg/ml. The lower range of the written reference range (200-400) is not healthy. The desired blood levels for vitamins are often controversial, and various medical colleges issue new recommendations on Vitamin D levels each month. Consequently, doctors must determine which level of Vitamin D to recommend for their patients. These institutions not only provide changing reference ranges but also offer differing advice on how frequently to test Vitamin D. This inconsistency arises primarily from the ongoing debate about the minimum acceptable level of Vitamin D. I have more information about your lab results next week that your doctor may not share with you. There is a lot of controversy surrounding the reference ranges on the lab sheet, and you should know the truth in case your doctor doesn't.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Aaron Logan, MD, PhD Although acute lymphoblastic leukemia (ALL) is a relatively rare disease with fewer than 7,000 people diagnosed each year in the US,1,2 there's been a lot of progress in the management of B-cell ALL over the years. One key development comes from the E1910 Phase III trial, which explored the addition of blinatumomab to frontline consolidation chemotherapy for patients with Philadelphia chromosome-negative B-lineage ALL (B-ALL).3 Joining Dr. Charles Turck to discuss the impacts of this data on B-ALL clinical guidelines and practice is Dr. Aaron Logan. Dr. Logan is a Professor of Clinical Medicine in the Division of Hematology/Oncology and Director of the Hematologic Malignancies Tissue Bank at UCSF. References: National Cancer Institute. SEER Cancer Stat Facts: Acute Lymphocytic Leukemia (ALL). Accessed at https://seer.cancer.gov/statfacts/html/alyl.html on March 31, 2025 Dana-Farber Cancer Institute. Acute Lymphoblastic Leukemia (ALL). Accessed September 17, 2024. https://www.dana-farber.org/cancer-care/types/acute-lymphoblastic-leukemia Litzow MR, et al. Blood. 2022;140(suppl 2):LBA-1

Osteoporosis remains a significant health concern, with new screening and treatment guidelines aiming to improve prevention and care. This episode explores updated recommendations, the latest therapeutic options, and how medications for other conditions can impact bone health. Stay informed and ready to support your patients—tune in to learn how pharmacists can make a difference. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTErin Raney, PharmD, BCPS, BC-ADMProfessorMidwestern University College of Pharmacy, Glendale CampusPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the updated screening and treatment guidelines for osteoporosis and their implications for patient care.2. Identify medications that affect bone health strategies for pharmacists to mitigate their impact on osteoporosis risk.0.05 CEU/0.5 HrUAN: 0107-0000-25-088-H01-PInitial release date: 4/7/2025Expiration date: 4/7/2026Additional CPE details can be found here.

Osteoporosis remains a significant health concern, with new screening and treatment guidelines aiming to improve prevention and care. This episode explores updated recommendations, the latest therapeutic options, and how medications for other conditions can impact bone health. Stay informed and ready to support your patients—tune in to learn how pharmacists can make a difference.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTErin Raney, PharmD, BCPS, BC-ADMProfessorMidwestern University College of Pharmacy, Glendale CampusPharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the updated screening and treatment guidelines for osteoporosis and their implications for patient care.2. Identify medications that affect bone health strategies for pharmacists to mitigate their impact on osteoporosis risk.0.05 CEU/0.5 HrUAN: 0107-0000-25-088-H01-PInitial release date: 4/7/2025Expiration date: 4/7/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Hadfield, MD Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential. Joining Dr. Charles Turck to discuss these key considerations for subcutaneous cancer immunotherapies is Dr. Matthew Hadfield, Assistant Professor of Medicine at Brown University/Alpert School of Medicine.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kaitlin Batley, MD Guest: Esra Caylan, MD Thymidine kinase 2 deficiency (TK2d) presents with a variability of symptoms, including respiratory, neurological, and ocular ones, making it difficult to diagnose. Because of this, a multidisciplinary care team that's tailored to each patient's needs is key to effectively identifying and treating this disease. Hear about the role of a multidisciplinary team and strategies for personalizing treatment with Drs. Kaitlin Batley and Esra Caylan. Dr. Batley is the Director of Pediatric Neuromuscular Medicine at Children's Health and an Assistant Professor at UT Southwestern Medical Center. Dr. Caylan is a pediatric pulmonologist at Children's Health and an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, joined Over the Counter to discuss pharmacists' role in counseling patients on GLP-1s as well as the common trends, challenges, and successes she's seen among her patient population. 

Listen in as our expert panel discusses which diabetes meds have cardiovascular (CV) benefits.  We'll review the evidence and discuss the pros and cons of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc) and GLP-1 agonists (dulaglutide, semaglutide, etc) in patients with or at risk for CV disease.Special Guests:Lauren G. Pamulapati, PharmD, BCACPAssociate Professor, Ambulatory CareVirginia Commonwealth University School of PharmacyClinical Pharmacist, Hayes Willis Health Center/VCU HealthChristie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCPProfessor, Pharmacy PracticeDirector, PGY2 Ambulatory Care Residency ProgramMidwestern University College of Pharmacy, Downers Grove CampusClinical Pharmacist, Northwestern MedicineTRC Editorial Advisory Board Participant:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleFor the purposes of disclosure, Dr. Schumacher reports a relevant financial relationship [CGM for diabetes management] with Abbott (speakers bureau).The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in February 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Chart: Diabetes Medications: Cardiovascular and Kidney ImpactChart: Drugs for Type 2 Diabetes Algorithm: Stepwise Treatment of Type 2 DiabetesChart: Comparison of GLP-1 AgonistsToolbox: Improving Heart Failure CareSend us a textIf you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence Educational Objectives Examine best practices for optimizing medication adherence and treatment initiation in hypercholesterolemia management Explain patient education and counseling for managing hypercholesteremia Faculty: Joseph Saseen, PharmD, BCPS, BCACP, CLS Professor and Associate Dean for Clinical Affairs University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Executive Director, Ambulatory Pharmacy Services Grady Health System Atlanta, Georgia Joseph Saseen, PharmD, BCPS, BCACP, CLS, has the following financial relationships with commercial interests to disclose: Other Support (Lipid Monitoring Committee): Amgen (VESALIUS and OCEAN(a))   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Novartis Consultant: Novartis, Regeneron   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-9999-25-069-H01-P. The activity is available for CE credit through March 31, 2026.   This activity is jointly provided by the University of Connecticut School of Pharmacy–Storrs and Pharmacy Times Continuing Education™, and is supported by an educational grant from Novartis Pharmaceuticals Corporation.   Please follow the link below to access this activity on PTCE and claim CE credit: www.pharmacytimes.org/hyperlipidemiapodcast

Hormone replacement therapy (HRT) remains a cornerstone of managing menopausal symptoms, but understanding the latest evidence is crucial for safe and effective use. This episode dives into evidence-based therapies, weighing benefits and risks and highlighting the pharmacist's role in guiding personalized care. Tune in to stay updated on the science behind HRT and its evolving role in patient care. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTAshley Meredith, PharmD, MPH, BCACP, BCPS, CDCES, FCCPClinical ProfessorPurdue UniversityPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the latest evidence-based approaches to hormone replacement therapy (HRT) for managing menopausal symptoms.2. Identify key considerations for pharmacists when counseling patients on the benefits, risks, and appropriate use of HRT.0.05 CEU/0.5 HrUAN: 0107-0000-25-087-H01-PInitial release date: 3/31/2025Expiration date: 3/31/2026Additional CPE details can be found here.

Hormone replacement therapy (HRT) remains a cornerstone of managing menopausal symptoms, but understanding the latest evidence is crucial for safe and effective use. This episode dives into evidence-based therapies, weighing benefits and risks and highlighting the pharmacist's role in guiding personalized care. Tune in to stay updated on the science behind HRT and its evolving role in patient care.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTAshley Meredith, PharmD, MPH, BCACP, BCPS, CDCES, FCCPClinical ProfessorPurdue University Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the latest evidence-based approaches to hormone replacement therapy (HRT) for managing menopausal symptoms.2. Identify key considerations for pharmacists when counseling patients on the benefits, risks, and appropriate use of HRT.0.05 CEU/0.5 HrUAN: 0107-0000-25-087-H01-PInitial release date: 3/31/2025Expiration date: 3/31/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence Educational Objectives Examine best practices for optimizing medication adherence and treatment initiation in hypercholesterolemia management Explain patient education and counseling for managing hypercholesteremia Faculty: Joseph Saseen, PharmD, BCPS, BCACP, CLS Professor and Associate Dean for Clinical Affairs University of Colorado Anschutz Medical Campus Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora, Colorado   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Executive Director, Ambulatory Pharmacy Services Grady Health System Atlanta, Georgia Joseph Saseen, PharmD, BCPS, BCACP, CLS, has the following financial relationships with commercial interests to disclose: Other Support (Lipid Monitoring Committee): Amgen (VESALIUS and OCEAN(a))   Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, has the following financial relationships with commercial interests to disclose: Grant/Research Support: Novartis Consultant: Novartis, Regeneron   Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-9999-25-069-H01-P. The activity is available for CE credit through March 31, 2026.   This activity is jointly provided by the University of Connecticut School of Pharmacy–Storrs and Pharmacy Times Continuing Education™, and is supported by an educational grant from Novartis Pharmaceuticals Corporation.   Please follow the link below to access this activity on PTCE and claim CE credit: www.pharmacytimes.org/hyperlipidemiapodcast

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its origin. Questions have remained regarding the risk of cancer for those patients with a CSD MCED result, followed by a diagnostic evaluation that did not result in a cancer diagnosis and a second MCED test. Recent research was conducted to help address this gap, and now, Dr. Eric Klein joins Dr. Charles Turck to share the real-world outcomes following a Galleri MCED retest. Dr. Klein is a distinguished scientist at Grail and one of the elite investigators on the clinical studies that led to the development of the Galleri MCED test.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Eric Klein, MD With an urgent need to screen for cancer, clinical trials have shown that the multi-cancer early detection (MCED) test Galleri® can screen for more than 50 distinct cancer types in adults 50 and over and predict its origin. Questions have remained regarding the risk of cancer for those patients with a CSD MCED result, followed by a diagnostic evaluation that did not result in a cancer diagnosis and a second MCED test. Recent research was conducted to help address this gap, and now, Dr. Eric Klein joins Dr. Charles Turck to share the real-world outcomes following a Galleri MCED retest. Dr. Klein is a distinguished scientist at Grail and one of the elite investigators on the clinical studies that led to the development of the Galleri MCED test.

Our guest: Hossam Gamal, PharmD, BCPS, MBAWelcome to Drug Diversion Insights. In today's episode, we're diving into a critical conversation about hospital drug diversion programs and the evolving landscape of regulatory oversight. I'm joined by Dr. Hossam Gamal, an experienced Pharmacy Director who brings valuable insights into how surveyors are increasingly scrutinizing diversion mitigation efforts.Recent trends suggest a significant shift in how facilities are being evaluated - moving beyond simply checking boxes to requiring truly meaningful diversion programs. Dr. Gamal will share his firsthand experiences with recent surveys, discussing how regulators are examining program effectiveness, the role of monitoring software, and the essential components of a robust diversion response strategy.We'll explore whether surveyors are equipped with the necessary technical knowledge to evaluate these programs effectively, drawing parallels to similar challenges faced in other areas of healthcare compliance. Of particular interest is Dr. Gamal's perspective on establishing clear criteria for activating diversion response teams - a critical yet often overlooked aspect of comprehensive diversion mitigation.This conversation comes at a crucial time when healthcare facilities nationwide are reevaluating their approach to diversion mitigation. Whether you're a healthcare administrator, pharmacy professional, or compliance officer, today's discussion will provide valuable insights into creating and maintaining effective diversion programs that meet increasingly rigorous regulatory expectations.Thanks to our sponsor, MIDAS Healthcare SolutionsLearn more about V.I.E.W. Waste and Return System: https://midashs.com/products/For more information on Drug Diversion mitigation and resources, visit: https://www.rxpert.solutions/#drugdiversion #hospitalpharmacy #opioidcrisis #hospitalworker

Tapering antidepressants requires careful planning to minimize withdrawal symptoms and ensure patient safety. This episode provides pharmacists with a brief update on antidepressant therapies and essential education on tapering, including recognizing withdrawal risks, adjusting schedules, and counseling patients effectively. Don't miss this opportunity to stay informed and enhance your skills in supporting patients through their mental health treatment journey. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTSara Grady, PharmD, BCPS, BCPPProfessor, Clinical PharmacistDrake UniversityBroadlawns Medical CenterPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanisms of action of antidepressant therapies and their implications for patient care. 2. Explain best practices for tapering antidepressants, including recognizing withdrawal risks and providing effective patient counseling.0.05 CEU/0.5 HrUAN: 0107-0000-25-075-H01-PInitial release date: 3/24/2025Expiration date: 3/24/2026Additional CPE details can be found here.

Tapering antidepressants requires careful planning to minimize withdrawal symptoms and ensure patient safety. This episode provides pharmacists with a brief update on antidepressant therapies and essential education on tapering, including recognizing withdrawal risks, adjusting schedules, and counseling patients effectively. Don't miss this opportunity to stay informed and enhance your skills in supporting patients through their mental health treatment journey.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTSara Grady, PharmD, BCPS, BCPPProfessor, Clinical PharmacistDrake UniversityBroadlawns Medical CenterPharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the mechanisms of action of antidepressant therapies and their implications for patient care. 2. Explain best practices for tapering antidepressants, including recognizing withdrawal risks and providing effective patient counseling.0.05 CEU/0.5 HrUAN: 0107-0000-25-075-H01-PInitial release date: 3/24/2025Expiration date: 3/24/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

In this captivating episode of Taking Healthcare by Storm, delve into the world of expert insights as Quality Insights Medical Director Dr. Jean Storm engages in a thought-provoking and informative discussion with Donna Lisi, PharmD, BS Pharmacy, BCPS, BCPP, BCACP, BCGP, BCMTMS, FASCP, FAAPP, a board-certified pharmacotherapy specialist and board-certified psychiatric pharmacist.Dr. Lisi discusses the importance of immunizations for older adults, addressing vaccine hesitancy, immunosenescence, and barriers like healthcare access. She highlights pharmacists' expanding role, community outreach, culturally competent education, and AI in improving vaccine uptake and infectious disease management. If you have any topics or guests you'd like to see on future episodes, reach out to us on our website. Publication number QI-032125-GK

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Anthony Stein, MD Could a novel triplet combination therapy offer a new path forward in acute myeloid leukemia (AML) treatment? A recent Phase 1B trial explored the potential of tagraxofusp, azacitidine, and venetoclax for AML patients. To discuss the findings on this triplet combination therapy, Dr. Charles Turck speaks with Dr. Anthony Stein, Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

Hypertension remains a leading contributor to cardiovascular disease, but advancements in its management are reshaping treatment strategies. This episode highlights the latest updates in hypertension guidelines, emerging therapies, and practical approaches pharmacists can use to optimize care. Don't miss this chance to stay informed and elevate your role in improving patient outcomes.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTJoseph Saseen, PharmD, BCPS, BCACP, CLS, ASH-CHCProfessor and Associate Dean for Clinical AffairsUniversity of ColoradoPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe recent updates in hypertension management guidelines and their implications for patient care.2. Identify emerging therapies and evidence-based strategies pharmacists can use to optimize hypertension treatment and improve outcomes.0.05 CEU/0.5 HrUAN: 0107-0000-25-058-H01-PInitial release date: 3/10/2025Expiration date: 3/10/2026Additional CPE details can be found here.

Hypertension remains a leading contributor to cardiovascular disease, but advancements in its management are reshaping treatment strategies. This episode highlights the latest updates in hypertension guidelines, emerging therapies, and practical approaches pharmacists can use to optimize care. Don't miss this chance to stay informed and elevate your role in improving patient outcomes.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTJoseph Saseen, PharmD, BCPS, BCACP, CLS, ASH-CHCProfessor and Associate Dean for Clinical AffairsUniversity of Colorado Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe recent updates in hypertension management guidelines and their implications for patient care. 2. Identify emerging therapies and evidence-based strategies pharmacists can use to optimize hypertension treatment and improve outcomes.0.05 CEU/0.5 HrUAN: 0107-0000-25-058-H01-PInitial release date: 3/10/2025Expiration date: 3/10/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Yi Bin Chen, MD Guest: Olaf Penack, MD For the past several decades, standard treatment for acute graft-versus-host disease (aGVHD) has been systemic high-dose steroids.1 While essential in some ways to initially control aGVHD, steroids are not beneficial in the long run due to the immunosuppression and toxicities associated with high cumulative doses.1,2 So what can be done moving forward to improve first-line steroid response and minimize cumulative steroid exposure? Joining Dr Charles Turck to discuss the potential of nonimmunosuppressive steroid-sparing agents for the first-line treatment of aGVHD are Drs Yi Bin Chen and Olaf Penack. Dr Chen is the Director of the Hematopoietic Cell Transplant and Cell Therapy Program at Massachusetts General Hospital, and Dr Penack is a senior physician and principal investigator within Hematology and Oncology at Charité Berlin. References: Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease. Transplant and Cell Ther. 2022;28(10):707.e1-707.e7. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(8):1150-1163. © 2025 CSL BehringCMD-964-0016-JAN25

In this episode, Sharmeen Roy, PharmD, BCPS, Chief Strategy & Science Officer at DoseMeRx, discusses the power of precision dosing technology in optimizing pharmacy operations and improving patient outcomes. Learn how validated, EHR-integrated software is enhancing clinical efficiency, reducing errors, and personalizing medication management.

In this episode, listen in as our expert panel digs into identifying and treating acute bronchitis and community-acquired pneumonia. They'll discuss when antibiotics are appropriate, which antibiotics to use, and other management tips.You'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLM, Program Director for the Prisma Health/USC School of Medicine Greenville Family Medicine Residency Program and Clinical Associate Professor at the University of South Carolina School of Medicine, GreenvilleAndrea Darby Stewart, MD, Associate Director, Honor Health Family Medicine Residency Program and Clinical Professor of Family, Community & Occupational Medicine at the University of Arizona College of Medicine - PhoenixCraig D. Williams, PharmD, FNLA, BCPS, Clinical Professor of Pharmacy Practice at the Oregon Health and Science UniversityNone of the speakers have anything to disclose.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in January 2025.TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter, or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Chart: Managing Community-Acquired Pneumonia and Aspiration Pneumonia in AdultsFAQ: Antibiotic Therapy: When Are Shorter Courses Better?Chart: Managing Cough and Cold SymptomsSend us a textCheck out our NEW podcasts. Rumor vs TruthYour trusted source for facts... where we dissect the evidence behind risky rumors and reveal clinical truths.Clinical CapsulesTRC editors break down the most impactful clinical developments - giving you clear, actionable takeaways in just minutes.If you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Join the conversation with C4 & Bryan Nehman.  C4 & Bryan kicked off todays show by discussing the DLS audit of BCPS.  There were two more near misses at airports across the country yesterday.  An update to the Adnan Syed case.  DeCosta & Harbaugh comments on the Justin Tucker situation.  A UMBC poll on energy.  Former State Senator Jim Brochin joined the show discussing the BGE bill situation & more.  21 employees resign from the US Digital Services amid the Elon Musk & DOGE "5 things i've done at work" email saga.  Listen to C4 & Bryan Nehman live weekdays from 5:30 to 10am on WBAL News Radio 1090, FM 101.5 & the WBAL Radio App.

Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, joined Over the Counter to discuss the 2025 Pharmacy Forecast and challenges within the business behind health-system pharmacies.

Discover the essential contributions of pharmacists in patient care with We're Your Pharmacist, a monthly podcast from ASHP. This episode features Emily Bryant, Clinical Pharmacist and Residency Program Coordinator at Aurora Health Care, as she shares insights on her pharmacy career journey, her experiences working with pharmacy students and residents, and the various roles of pharmacists as medication experts in a hospital setting. Gain insights into the diverse opportunities within the pharmacy profession and learn how pharmacists are making a difference every day. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Bispecific antibodies (BsAbs) have the potential to transform cancer treatment and are being actively integrated into community oncology practices. To support oncology practices as they introduce BsAbs into their treatment protocols, the Association of Cancer Care Centers (ACCC) has developed a comprehensive blueprint for this process. This resource highlights key strategies, best practices, and considerations for successful implementation. It gives guidance on capacity building, care coordination, and adverse event management, reflecting ACCC's commitment to providing education and expanding access to this innovative treatment for patients with cancer. In this episode, CANCER BUZZ speaks with Donald Moore, PharmD, clinical oncology pharmacy manager at Atrium Health Levine Cancer, about the role of bispecific antibodies in oncology care and unique challenges associated with interdisciplinary collaboration. Dr Moore also discusses how the new Blueprint is designed to empower cancer practices to optimize the rollout of these innovative therapies.     “I think that the blueprint really nicely describes and delineates some high-level roles and responsibilities of a community academic partnership and how both sites can collaborate to deliver care to their patients” – Donald Moore   “Ultimately, my hope is that the blueprint, along with some of the additional resources provided with it, will be helpful in bringing these new therapies closer to home for all of our patients... improving the access to care for this emerging drug class.” – Donald Moore   Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP  Clinical Oncology Pharmacy Manager  Division of Pharmacy   Atrium Health Levine Cancer  Charlotte, NC    Resources:   ACCC Best Practices for Expanding Access to BsAbs  - https://www.accc-cancer.org/home/learn/precision-medicine/treatment/bispecific-antibodies/best-practices-bispecific-antibodies   ACCC Operational Insights in Delivery of BsAbs - https://www.accc-cancer.org/home/learn/precision-medicine/treatment/bispecific-antibodies/bispecific-antibodies-in-solid-tumors   ASCO Use of BsAbs in Community Practices - https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e13575   AJMC Obstacles to Optimal Transition Between Academic and Community Centers - https://www.ajmc.com/view/obstacles-to-optimal-transitions-of-care-between-academic-and-community-settings-when-utilizing-bispecific-antibodies   ASH Multidisciplinary Provider Insights for Promotion of BsAbs in the Community - https://ashpublications.org/blood/article/138/Supplement%201/4033/481457/Multidisciplinary-Provider-Insights-to-Promote    

Guest: Shalini Prasad, PhD Guest: Sriram Muthukumar, PhD Host: Charles Turck, PharmD, BCPS, BCCCP With the constant ups and downs of inflammatory bowel disease (IBD), consistent monitoring can help provide patient-centric care. Dr. Shalini Prasad and Dr. Sriram Muthukumar, co-founders of EnLiSense, join GI Insights to discuss the wearable device they developed to track inflammation markers in IBD patients. Dr. Prasad is the Head of the Department of Bioengineering at the University of Texas at Dallas, and Dr. Muthukumar is the CEO of EnLiSense.

The "Pharmacy 50" Awards, recognizing the 50 Most Influential Leaders in Pharmacy, have officially been announced for 2024! This prestigious honor celebrates the most inspiring, innovative, and impactful figures in pharmacy who are driving advancements in patient care, business development, and industry reform. Now in its fourth year, the Pharmacy 50 saw a record-breaking 30% increase in peer recognition, demonstrating the growing influence of pharmacists across multiple sectors, including Community Pharmacy, Long-Term Care, Specialty Pharmacy, Health System, Digital Health, and more. Voting took place between November 15 and December 20, 2024, and this year's winners include some of the most distinguished names in the industry, with returning honorees and new leaders making their mark on pharmacy's evolving landscape.   Pharmacy 50 Class of 2024 (Listed by most votes) Anthony V. Minniti, BScPharm, RPh, FACA Jay Phipps, PharmD, MBA, FACA, FACVP Dr. Nhu Truong, PharmD Jeff Harrell, PharmD Naveena Gorrepati, PharmD Jeremy Counts, PharmD Darshan Kulkarni, PharmD, Esq. Shahida Choudhry, PharmD** (4-time winner) April Nguyen, PharmD, RAC, MPH Robin Barrett, PharmD Cody R. Morcom, PharmD, BCPS, LSSGBC Ethan Melillo, PharmD, CDOE Randy McDonough, PharmD, MS, BCGP, BCPS, FAPhA Chelsea Hustad, PharmD, CSP Greg Reybold, Esq. Renee Malarbi Rayburg, BPharm Walter Oronsaye, PharmD, MS Chidimma Gold Eneyo, PharmD Jessica Beal-Stahl, PharmD Tamar K. Lawful, PharmD, APh, CNGS DeLon Canterbury, PharmD, BCGP Frank Harvey, MBA Mike Johnston, CPhT-Adv Brent Edison, PharmD Aleata Postell Courtney B. Smith, PharmD, CSP, BCMTMS Jennifer Morrison, PharmD Katrina Azer, BPharm Josh Pirestani Bil Schmidtknecht Ultan McGlone, PharmD Katarina (Kati) Forbes, PharmD Christopher Bowens, PharmD Mahmoud Zegar, PharmD Alexandra (Ally) LaStella, PharmD Kunal Vyas Jenny Bingham, PharmD Shaun Jensen Fiona Sartoretto Verna Brandi Chane, PharmD Jonathan Ogurchak, PharmD, CSP, CPHIMS Jena Quinn, PharmD Jordan Smith, PharmD, AAHIVP, CPGx Chris Antypas, PharmD Lorneka Joseph, PharmD Derek Borkowski, PharmD Sue Ojageer, PharmD, CPGx Benjamin Jolley, PharmD Anisha Patel, BPharm Jeff Malone Pharmacy 50 Awards Ceremony - January 29, 2025 The official awards ceremony will be hosted at the Pharmacy Podcast Network headquarters in Brownsville, PA. The event will feature: A networking session at 2 PM ET The Pharmacy 50 LIVE Stream at 3 PM ET, where winners will be highlighted and interviewed Industry leaders, past winners, and special guests will be in attendance to celebrate the remarkable contributions of these pharmacy professionals. The Pharmacy 50 Awards were created to recognize individuals who are pushing the boundaries of pharmacy care. From technology and advocacy to clinical services and business innovation, this year's winners represent the best of the best across the pharmacy profession. "Each year, we see more pharmacists taking charge of their profession-leading change, innovating care models, and fighting for patient access. The Pharmacy 50 recognizes these change-makers and amplifies their voices," said Todd Eury, Founder of Pharmacy Podcast Network. This year's Pharmacy 50 Awards were proudly sponsored by RxInsider and Independent Pharmacy Cooperative (IPC), whose ongoing support of the pharmacy industry continues to fuel growth and advocacy. "RXinsider is thrilled to support the Pharmacy Podcast Network's Pharmacy50 Awards, celebrating the outstanding leaders and innovators shaping pharmacy. As a company committed to advancing pharmacy through education and innovation, RXinsider is honored to join this prestigious initiative that recognizes excellence and inspires progress." stated Gregory Cianfarani RPh, CEO of RxInsider. "We're excited to celebrate the achievements of our peers and contribute to highlighting the individuals and organizations making a meaningful impact in the pharmacy community." For more details about the Pharmacy 50 Awards, visit Pharmacy50.us About Pharmacy Podcast Network (PPN) Pharmacy Podcast Network is the leading media platform dedicated to pharmacy professionals, offering thought leadership, industry insights, and expert-driven content through podcasts, webinars, and live events. Since its founding in 2009, PPN has been the voice of pharmacy, covering community pharmacy, specialty pharmacy, digital health, advocacy, business development, and more.

In this episode, TRC Healthcare editors, Sara Klockars, PharmD, BCPS, and Stephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSC, discuss notable new meds of 2024. Listen in as our editors discuss several novel drugs approved in 2024...and highlight some medications now available in a new dosage form. They'll review efficacy, safety, and considerations for use with these new treatment options.  None of the speakers have anything to disclose. TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter, or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditThe clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: On Demand Webinar: Notable New Meds of 2024Articles: Clarify the Role of Sofpironium for HyperhidrosisWatch for Ensifentrine for COPDDon't Rush to Aprocitentan for Resistant HypertensionNew Drug for Schizophrenia Targets Muscarinic ReceptorsBe Familiar With Carbidopa/Levodopa OptionsNew Drug Overviews:Aprocitentan (Tryvio)Epinephrine Nasal Spray (Neffy)Send us a textCheck out our NEW podcasts. Rumor vs TruthYour trusted source for facts... where we dissect the evidence behind risky rumors and reveal clinical truths.Clinical CapsulesTRC editors break down the most impactful clinical developments - giving you clear, actionable takeaways in just minutes.If you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Miguel-Angel Perales, MD Guest: Anna Sureda, MD, PhD Unfortunately, the treatment paradigm for acute graft-versus-host disease (aGVHD) has not changed for a couple of decades as steroids remain the first-line treatment.1 However, steroids are not a targeted therapy, and they have many side effects that are not well tolerated by patients, including life-threatening infections.1-3 Given these risks, it is important to know how to manage infections related to immunosuppression and optimize the care of patients with aGVHD. Joining Dr Charles Turck to discuss the current landscape of aGVHD management are Dr Miguel-Angel Perales and Dr Anna Sureda. Dr Miguel-Angel Perales is the Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York, and Dr Sureda is the Head of Clinical Hematology at the University of Barcelona in Spain. References: Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease. Transplant Cell Ther. 2022;28(10):707.e1-707.e7. doi:10.1016/j.jtct.2022.04.014 Sullivan PW, Ghushchyan VH, Globe G, Sucher B. Health-related quality of life associated with systemic steroids. Qual Life Res. 2017;26(4):1037-1058. García-Cadenas I, Rivera I, Martino R, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow …

In this episode, TRC Healthcare editors, Sara Klockars, PharmD, BCPS, and Stephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSC, tackle the topic of Natural Medicines. Listen in as they define what natural medicines are... and discuss the safety and efficacy of several natural medicines, including ashwagandha, berberine, and turmeric.  They'll also discuss how to navigate discussions with patients about supplements, including tips for choosing a quality supplement.  None of the speakers have anything to disclose. TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter, Pharmacy Technician's Letter, or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.Claim CreditYou can find more about these topics with resources that are part of a subscription to Pharmacist's Letter, Pharmacy Technician's Letter, and Prescriber Insights: Article: Be Prepared With Guidance About AshwagandhaArticle: Don't Recommend Berberine as a GLP-1 Agonist AlternativeArticle: Give Guidance About Coenzyme Q10Article: Clarify the Effectiveness and Safety of MelatoninArticle: Be Prepared With Advice About Turmeric If you're not yet a subscriber, find out more about our product offerings at trchealthcare.com. Follow, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sun-Ho Lee, MD, PhD Recent research explored the development, validation, and implications of the GEM integrative risk score (GEM-IRS). To learn how this innovative model helps predict the future risk of Crohn's Disease in healthy first-degree relatives, Dr. Charles Turck speaks with Dr. Sun-Ho Lee, Assistant Professor and clinician scientist at the Inflammatory Bowel Disease Centre at Mount Sinai Hospital in Toronto, Canada.

Four pharmacist entrepreneurs share their journeys from pharmacy to thriving businesses, offering tips, actionable advice and inspiration. This episode is brought to you by APhA. Summary In this engaging panel discussion, four pharmacist entrepreneurs—Brooke Griffin, Jimmy Pruitt III, Kelley Carlstrom, and Natalie Park—share their unique paths from pharmacy to thriving businesses. Discover how they built their ventures, made strategic decisions, and overcame challenges along the way. Gain practical insights into audience building, pricing strategies, navigating sales, and balancing personal and professional growth.  Whether you're dreaming up a new idea or ready to expand your business, this episode is packed with actionable advice and inspiration to help you take the next step in your entrepreneurial journey. About Today's Guests Kelley Carlstrom is the CEO and founder of KelleyCPharmD, an education company that fills the considerable gap in clinical oncology training. She is passionate about democratizing oncology pharmacy education and increasing accessibility and inclusion through her unique L.E.A.R.N Oncology Method. Brooke Griffin is a pharmacist, professor, keynote speaker, and professional coach. She offers group and 1:1 coaching for pharmacists who are feeling stuck and want clarity on their next steps. She hosts a motivational 5-minute podcast, Today's Bold Idea, and is on this self-discovery journey alongside all of you. She believes everyone deserves a coach! Dr. Natalie Park is a co-founder and CEO of Pharmesol, an AI pharmacy assistant that automates inbound/outbound calls, messages, and associated workflows such as documentation to save the pharmacy teams time, streamlines operations, and gives 24/7 concierge-like experience for their customers. She is a pharmacist with a passion for leveraging technology and innovation in the pharmacy industry. Jimmy Pruitt III, PharmD, BCPS, BCCCP, BCEMP, a pharmacist and entrepreneur, earned his Doctor of Pharmacy degree from Presbyterian College and completed residencies at Florida Hospital Orlando and Grady Health System. He founded EMPowerRX Conference and Pharmacy & Acute Care University (PACU) to innovate healthcare education and inspire pharmacists to pursue entrepreneurship. In 2021, he received the Excellence in Diversity award and was named Alumni of the Year at Presbyterian College. Dr. Pruitt is also an Emergency Medicine Clinical Pharmacy Specialist at Atrium Health and hosts the "Pharm So Hard" podcast, aiming to educate and elevate the pharmacy profession. Mentioned on the Show Start by Jon Acuff Brooke Griffin on LinkedIn Kelley Carlstrom on LinkedIn Natalie Park on LinkedIn Jimmy Pruitt III on LinkedIn YFP Disclaimer Subscribe to the YFP Newsletter Tim Ulbrich on LinkedIn YFP on Instagram YFP Facebook Group  

Leigh Briscoe-Dwyer, PharmD, BSPharm, BCPS, FASHP, serves as President of the American Society of Health-System Pharmacists (ASHP). She has also served in various organizations and professional societies in New York. We talk through her current presidential year with ASHP and her message of telling your stories that coincides with ASHP's ‘We Are Your Pharmacist' campaign. She is passionate about pharmacy and you'll hear the top issues she is focused on this year!

Human rabies cases are fortunately rare in the US. Access to pre- and post-exposure prophylaxis, and domestic animal vaccination programs, drive this public health success. This comes at a financial and human resources cost. Dr. Kyle Weant, clinical assistant professor and an emergency medical clinical pharmacy specialist at the University of South Carolina College of Pharmacy and Dr. Philippe Mentler, senior consulting director, join host Gretchen Brummel to discuss the use of rabies immune globulin and rabies vaccine in patients who have been exposed and provide treatment pearls for frontline pharmacy practioners.   Guest speakers: Kyle Weant, PharmD, BCPS, BCCCP, FCCP Clinical Assistant Professor and an Emergency Medical Clinical Pharmacy Specialist University of South Carolina College of Pharmacy   Philippe Mentler, PharmD, BCPS Senior Consulting Director Vizient   Host:  Gretchen Brummel, PharmD, BCPS   Show Notes:  [00:54-01:17] Kyle's background information  [01:18-03:31] Rabies as a disease [03:32-05:13] Public Awareness [05:14-07:06] Options right now for post-exposure prophylaxis [07:07-10:01] Thoughts on dose rounding [10:02-10:13] Is rabies immunoglobulin considered an essential medication that everyone should stock in their hospital pharmacy [10:14-11:30] Who should be administering these drugs? And who's ensuring follow up of these patients? [11:31-14:31] Potential pitfalls in patient management [14:32-18:12] What should our frontline pharmacy staff know about post-exposure prophylaxis   Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed

Hot flashes may be the most talked-about symptom of menopause, but how much do you know about managing them for your patients? In this episode, we uncover treatment options, debunk common myths, and explore how pharmacists can offer crucial support during this transition. Tune in to empower your patients with the knowledge and care they need—don't miss an opportunity to get the latest on this “hot” topic!HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTAnna Garrett, PharmD, BCPS, AFMCPCEODr. Anna GarrettPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the physiological mechanisms behind hot flashes during menopause and their impact on a patient's quality of life.2. Identify treatment options for managing hot flashes that pharmacists can recommend to patients experiencing menopause.0.05 CEU/0.5 HrUAN: 0107-0000-24-308-H01-PInitial release date: 12/2/2024Expiration date: 12/2/2025Additional CPE details can be found here.

Explore the essential contributions of health-system pharmacists through engaging interviews with pharmacists and other healthcare team members who witness their impact firsthand. Nearly one in three pharmacists work beyond retail settings, bringing their specialized expertise in medications to hospitals, clinics, and outpatient facilities. As trusted partners on the healthcare team, these pharmacists work to ensure that medications are safe, effective, and accessible, playing a critical role in each patient's journey. Listen in as we uncover the many ways pharmacists make a difference.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

phactMI, a 501 (c)(6) corporation, is a collaboration of pharmaceutical company Medical Information leaders. These Medical Information professionals provide accurate and unbiased clinical data on their products that facilitates the safe and effective use of medicines.   But how does Medical Information partner and function within the pharmaceutical industry organization?  Join us in this episode as Evelyn Hermes-DeSantis, PharmD, BCPS, Director, Research and Publications, phactMI/ Professor Emerita, Rutgers The State University of New Jersey and guest speakers Drs. Stacey Fung, Leena Jindia, and Vatche Demirjian discuss the value of Medical Information and collaborative process behind accurate drug information. The objectives of this podcast are to: • Describe the value of Medical Information within a pharmaceutical company from drug development to patient safety.  • Discuss the collaborative process behind creating and maintaining accurate drug information.  • Identify the future of drug information sharing and how phactMI plays a role. Learn more about phactMI at: www.phactMI.org/about/

Despite advances in the management of acute myocardial infarction (MI), up to 38% of patients will experience signs of heart failure (HF) and many have a reduced left ventricular ejection fraction (LVEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented cardiovascular benefits. However, data are limited regarding their use after an acute MI. Guest Authors: Amy Hu, PharmD and Kathleen Pincus, PharmD, BCPS, BCACP, CDCES Music by Good Talk

What does it take to build confident readers? Just ask educators at Baltimore City Public Schools, where students are outpacing the rest of the state in English Language Arts thanks to a focus on literacy instruction and intensive professional development. In part two of our series on literacy, Gloria dives into how BCPS is engaging diverse, multilingual learners with Dr. Joan Dabrowski, Chief Academic Officer at BCPS, and Olia Hardy, Principal of William Paca Elementary. This episode is created in partnership with the Schusterman Family Philanthropies. Thank you to Baltimore City Public Schools for making this conversation possible.  See omnystudio.com/listener for privacy information.

phactMI, a 501 (c)(6) corporation, is a collaboration of pharmaceutical company Medical Information leaders. These Medical Information professionals provide accurate and unbiased clinical data on their products that facilitates the safe and effective use of medicines.   But where do pharmacists and other healthcare providers go for accurate information?   Join us in this episode as Evelyn Hermes-DeSantis, PharmD, BCPS, Director, Research and Publications, phactMI/ Professor Emerita, Rutgers The State University of New Jersey and guest speakers Drs. Indrani Kar, Daniel Abazia, and Jennifer Riggins discuss real world experiences in accessing drug information.  The objectives of this podcast are to: • Discuss the real-world challenges faced by healthcare professionals and how information helped them navigate the situation. • And to describe how to access information from the phactMI Drug Information Portal Learn more about phactMI at: www.phactMI.org/about/